Total Funding
93
86
Total FundingSeries B raised
Growth Score
-2 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
8076
Gallant is advancing investigational stem cell therapies to help give pets more good years, making regenerative care more accessible.
- Valentine Williams: Senior Vice President Clinical Development & Regulatory
- Sara Woods: Marketing DirectorPast Role: PwC, Global Strategic Marketing
About the Company
Gallant is developing a scalable stem cell therapy platform that will allow any veterinarian to routinely treat pets in a primary care setting, improving the lives of pets and their people. By systematically addressing challenges that previously hindered stem cell therapy adoption, the company aims to make stem cell products accessible in order to
elevate the quality of life for all pets and the people that love them.
